Valuation: Arctic Bioscience

Market Cap 80.87M 8.54M 7.4M 6.93M 6.32M 11.88M 814M 12.07M 81.5M 31.86M 408M 32.05M 31.36M 1.36B P/E 2026 *
-3.37x
P/E 2027 * -
Enterprise Value 147M 15.5M 13.43M 12.59M 11.48M 21.58M 1.48B 21.91M 148M 57.86M 740M 58.21M 56.95M 2.47B EV / Sales 2026 *
2.53x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.67%
1 week-3.17%
Current month+14.23%
1 month-6.15%
3 months+1.67%
6 months-10.03%
Current year-7.01%
1 week 2.82
Extreme 2.82
3.29
1 month 2.51
Extreme 2.51
3.4
Current year 2.51
Extreme 2.51
3.67
1 year 2.51
Extreme 2.51
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
4/24/23 Buy

Director

943,833 3.8641%
4/24/23 Buy

Director

943,833 3.8641%
2/23/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%-3.17%-10.29%-69.44% 8.51M
+0.53%+4.82%+91.77%+127.92% 1,083B
+0.41%+1.41%+51.19%+50.61% 626B
-0.66%+1.27%+25.52%+63.74% 442B
-0.92%+0.22%+48.34%+38.00% 363B
-1.32%-0.21%+29.07%+36.60% 295B
-1.20%-2.78%+5.56%+5.29% 248B
+0.75%+2.48%+46.66%+60.15% 224B
-2.51%+1.77%-6.55%-51.64% 210B
+0.81%+3.88%+14.04%+71.41% 168B
Average -0.29%+4.31%+29.53%+33.27% 365.91B
Weighted average by Cap. -0.21%+4.29%+49.64%+65.31%

Financials

2026 *2027 *
Net sales 58M 6.12M 5.3M 4.97M 4.53M 8.52M 584M 8.65M 58.46M 22.85M 292M 22.99M 22.49M 975M -
Net income -24M -2.53M -2.2M -2.06M -1.88M -3.53M -242M -3.58M -24.19M -9.46M -121M -9.51M -9.31M -403M -
Net Debt 66M 6.97M 6.04M 5.66M 5.16M 9.7M 665M 9.85M 66.52M 26M 333M 26.16M 25.59M 1.11B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-08-12 NOK 3.050 +1.67% 11,134
26-08-11 NOK 3.000 -1.96% 22,780
26-08-10 NOK 3.060 -2.86% 6,869
26-08-07 NOK 3.150 +2.94% 6,970
26-08-06 NOK 3.060 -2.86% 11,564
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise